A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Summary

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

Timeline

Start

2023-05-30

Primary completion

2026-04-16

Completion

2026-05

Outcome

Met primary endpoint

release “In both studies, retatrutide met the primary endpoint” lilly.com ↗

Drugs

Indications